Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI) had its target price boosted by research analysts at HC Wainwright from $32.00 to $42.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 86.92% from the company’s current price.

Other analysts have also recently issued reports about the stock. Wedbush decreased their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Robert W. Baird raised their target price on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Thursday. UBS Group started coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Thursday, January 8th. Finally, Wolfe Research assumed coverage on Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.70.

Denali Therapeutics Price Performance

Shares of DNLI opened at $22.47 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The company’s fifty day moving average price is $20.41 and its 200-day moving average price is $17.80. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $23.77. The firm has a market capitalization of $3.56 billion, a PE ratio of -7.57 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the previous year, the business posted ($0.67) earnings per share. On average, equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Activity

In related news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently modified their holdings of DNLI. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the second quarter worth about $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics during the 3rd quarter worth approximately $29,000. State of Wyoming acquired a new position in shares of Denali Therapeutics during the second quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Denali Therapeutics during the fourth quarter valued at approximately $57,000. Finally, Quarry LP purchased a new position in shares of Denali Therapeutics in the third quarter valued at approximately $64,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.